Rex Bionics

Rex Bionics operates in rehabilitation robotics, focusing on powered mobility for people with spinal cord injury, stroke, traumatic brain injury, and neurodegenerative disease. Its core differentiation is the REX platform’s hands-free, self-supporting, independently controlled design, which targets users who may not be able to support themselves while standing or walking. The company has described two principal market applications: REX for professional neuro-rehabilitation clinics and REX P for personal and homecare use. Comparable companies named in rehabilitation robotics market coverage include Cyberdyne, Ekso Bionics, Parker Hannifin, and ReWalk Robotics. Relative to larger or more commercially visible competitors, Rex Bionics appears to occupy a narrower specialist position centered on independent control and rehabilitation exercises rather than broad industrial exoskeleton applications. Its REXERCISES programs add a structured therapy layer around the hardware. The company’s 11 granted patents and two registered trademarks support an established intellectual-property base, while its modest employee band and limited current-position data suggest a smaller-scale commercial presence.

Rex Bionics was founded in 2007 and reached a major financing inflection point with a $1 million Series A in July 2012, followed by a $16.97 million venture round in May 2014. It went public on the London Stock Exchange on May 16, 2014, then raised $1.27 million through a grant in August 2014 and $2.56 million in post-IPO equity in June 2016. A further $5 million post-IPO equity round in September 2017 preceded the company’s acquisition by BioScience Managers Limited and delisting in August 2017, creating an unusual transition from public-market financing to private ownership. Later activity shows renewed capital support rather than high-volume expansion: Rex Bionics recorded a $6,174 grant in September 2023, $995,596 in post-IPO equity in January 2024, and a $13,487 grant in July 2024. The company is listed as active, but employee data remains in the 11–50 range and only one current position is identified. Overall, the trajectory reflects long-term product and financing development with intermittent funding, rather than clearly documented rapid hiring or scale-up.